Life Sciences BPO Market: Introduction
Transparency Market Research has published a new report titled, ‘Global Life Sciences BPO Market’. According to the report, the global life sciences BPO market was valued at ~US$ 214 Bn in 2018 and is projected to expand at a CAGR of ~8% from 2019 to 2027.
Broad and Growing Product Pipeline to Drive Adoption of Advanced Life Sciences BPO
Rise in demand for new drugs and novel therapies for treatment of diseases such as cancer and immunological disorders coupled with the evolving research & development process has increased the number of compounds in pipeline in the last decade. The development of biosimilar products, cellular therapy, and immune biological products has also contributed toward the advancing pipeline and need of stringent clinical trials in the past few years. This in turn drives the global life sciences BPO market.
Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1782
Efforts to Optimize Costs and Development Time
Escalating costs of conducting clinical trials, requirement of data quality, enrollment targets, financial demands regarding setting up of a clinical research practice, and other management related activities drive the outsourcing services. Outsourcing also improves the global reach with respect to drug development with minimum maintenance cost, as CROs are well-versed with regulatory requirements of various regions. According to the Tufts Center for the Study of Drug Development, outsourcing to CROs has supported companies in keeping R&D head counts stable, even though the number of active clinical trials across the world has increased by 80%. Moreover, trials outsourced to CROs are, on average, completed 30% sooner than in-house clinical trials, providing an average timesaving of four to five months.
Contract Manufacturing Organizations to Lead Global Market
Based on service type, the contract manufacturing organizations segment dominated the global market in 2018. Growth of the segment can be attributed to the low cost associated with the production of active pharmaceutical ingredients, as the companies do not have to buy equipment for manufacturing. Moreover, quick turnaround time contributes to the growth of the segment. The contract research organizations (CRO) segment is likely to expand at a high CAGR during the forecast period, owing to significant increase in the number of clinical trials and rise in the demand for new drugs. Significant increase in research and development costs, technological developments, and product innovation, which accounts for high R&D costs prompt several pharmaceutical and medical device companies to outsource preclinical services to CROs. This in turn augments the segment.
Request for Analysis of COVID19 Impact on Life Sciences BPO Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1782
Life Sciences BPO Market: Prominent Regions
North America held major share of the global life sciences BPO market in 2018. Growth of the market in the region can be attributed to increase in the number of clinical trials and rise in demand for biosimilars owing to patent expiry, which fuels the demand for rapid conduction of trials and regulatory approvals. Moreover, well-established health care infrastructure, rise in prevalence of chronic diseases in the region, presence of leading players, and surge in penetration of life sciences BPO across the paradigm of clinical trials from early-phase to late-phase studies propel the market in the region. Europe held the second largest share of the global life sciences BPO market in 2018. The region is considered a lucrative market for pharmaceutical manufacturers to conduct phase 1 clinical trials rather than the emerging countries due to the availability of highly qualified staff, quality of services & infrastructure, fluency in foreign language, and ability to handle multiple-country clinical trials.
Asia Pacific accounted for significant share of the global life sciences BPO market in 2018. The region comprises major countries such as India, China, Australia, and Japan. Japan accounted for the largest share of the life sciences BPO market in Asia Pacific in 2018. Increase in pricing pressure, high prices of raw ingredients, and the need to reduce cost of marketing have induced several pharmaceutical and nutritional manufacturers to outsource some of their business elements to developing countries.
Purchase Life Sciences BPO Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=1782<ype=S
Life Sciences BPO Market: Key Players
Manufacturers are adopting strategies such as acquisition, collaboration, and distribution to increase share in the global life sciences BPO market. In February 2020, Charles River Laboratories International, Inc. signed an agreement to acquire Citoxlab for US$ 510 Mn. Citoxlab is a non-clinical CRO specialized in regulated safety assessment services, non-regulated discovery services, and medical device testing. In January 2018, Charles River Laboratories International, Inc. completed the acquisition of KWS BioTest Limited for US$ 20.3 Mn. The latter is specialized in in-vitro and in-vivo discovery testing services for immuno-oncology and inflammatory & infectious diseases.
Leading players operating in the global life sciences BPO market are IQVIA, Laboratory Corporation of America Holdings, Syneos Health, Inc., Parexel International Corporation, PRA Health Sciences, Inc., Charles River Laboratories International, Inc., WuXi AppTec Co., Ltd., ICON plc, Medpace Holdings, Inc., and Pharmaceutical Product Development, LLC.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
Read More Reports: https://www.prnewswire.co.uk/news-releases/constant-technological-developments-and-research-to-drive-valuation-of-diagnostic-specialty-antibodies-market-worth-us-35-8-bn-by-2027-end-finds-tmr-831559392.html